GlycoMimetics, Inc.
9780 Medical Center Drive
Rockville
Maryland
20850
United States
Tel: 240-243-1201
Website: http://glycomimetics.com/
Email: info@glycomimetics.com
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
220 articles with GlycoMimetics, Inc.
-
The Market Publishers, Ltd. Release: Generic Drug Companies Discussed in New Research Report Recently Published at MarketPublishers.com
12/13/2011
-
Progress of GlycoMimetics, Inc.’s Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology
12/13/2011
-
GlycoMimetics, Inc. Inks Licensing Deal Worth Up to $340 Million with Pfizer Inc.
10/11/2011
-
GlycoMimetics, Inc. Announces Data Presentations on Lead Compound at American Society of Hematology Annual Meeting
12/8/2010
-
Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model
9/28/2010
-
Key GlycoMimetics, Inc. Patents Issue in the U.S.
7/14/2010
-
GlycoMimetics, Inc. Initiates Phase 2 Clinical Trial of Lead Candidate GMI-1070 in Sickle Cell Patients
6/24/2010
-
GlycoMimetics, Inc. Announces Two Oral Presentations on Lead Drug Candidate GMI-1070 at American Society of Hematology Annual Meeting
12/7/2009
-
GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round
10/21/2009
-
New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patients, GlycoMimetics, Inc. Study
9/3/2009
-
GlycoMimetics, Inc. Awarded National Institutes of Health (NIH) Grant to Study Drug Candidate in Diabetes
8/17/2009
-
Nature Reviews: Drug Discovery Article Describes Design of GlycoMimetics, Inc. Compounds and Newly “Druggable” Disease Targets
7/24/2009
-
Dana-Farber Cancer Institute Presents Results of GlycoMimetics, Inc.'s Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting
5/28/2009
-
GlycoMimetics, Inc. Completes Phase 1 Clinical Studies of Lead Drug Candidate
3/26/2009
-
GlycoMimetics, Inc. to Present New Results of Lead Candidate in Additional Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting
12/8/2008
-
GlycoMimetics, Inc. Commences Phase 1 Clinical Trial of Lead Drug Candidate
9/5/2008
-
GlycoMimetics, Inc. to Present Results of Lead Drug Candidate in Animal Models of Sickle Cell Disease at American Society of Hematology Annual Meeting
12/10/2007
-
GlycoMimetics, Inc. Highlights Advances in Lead Drug Candidate for Sickle Cell Patients at International Glycobiology Conference
7/20/2007
-
GlycoMimetics, Inc. Secures $15.4-Million In Series B
6/23/2006
-
Tech Council of Maryland Release: Area Life Science Companies Chosen To Make Presentations For Venture Funding At 2005 Mid-Atlantic Bio
10/12/2005